Hypoparathyroidism
Recent clinical, regulatory, research and industry developments relating to this disease.
Efficacy and Safety of mRNA Drug XH02 in the Treatment of Adult Hypoparathyroidism
Market withdrawal: Natpar (EMA)
Marketing authorisation: Yorvipath (EMA)
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 3 clinical trials expected to report results, the earliest in Q4 2026.
- 1 industry development reported.
- Q4 2026A Phase 2, Prospective, Multinational, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of AMOR-1 as a Treatment of Hypocalcemia Associated With Hypoparathyroidism by Replacement of Currently Used Calcium Supplements (CS) in Adults.
- Q4 2027A Pilot Study of Calcium Replacement Therapy in Postoperative Hypoparathyroidism
- Q2 2030An Expanded Cohort Study on the Safety and Efficacy of mRNA Nucleic Acid Drug XH-02 in Treating Adult Hypoparathyroidism
Clinical MilestonesViewHide
- 2026-08-14A Phase 2, Prospective, Multinational, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of AMOR-1 as a Treatment of Hypocalcemia Associated With Hypoparathyroidism by Replacement of Currently Used Calcium Supplements (CS) in Adults.Results expected Q4 2026
- 2026-05-18An Expanded Cohort Study on the Safety and Efficacy of mRNA Nucleic Acid Drug XH-02 in Treating Adult HypoparathyroidismResults expected Q2 2030
- 2026-05-11A Pilot Study of Calcium Replacement Therapy in Postoperative HypoparathyroidismResults expected Q4 2027
- 2026-01-08PaTHway CHINA TRIAL: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With HypoparathyroidismCompleted
- 2025-12-31Treatment With Indapamide in Patients With Post-Surgical HypoparathyroidismPrimary completion
Industry & MarketViewHide
- 2026-09-07[Review] Hypoparathyroidism: translating science from the laboratory to the clinicIndustry · The Lancet Diabetes & Endocrinology
Regulatory UpdatesViewHide
- 2026-07-01Product authorisation ended — Parathyroid HormoneNatpar is indicated as adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.
- 2026-09-07Industry[Review] Hypoparathyroidism: translating science from the laboratory to the clinicIndustry · The Lancet Diabetes & Endocrinology
- 2026-08-14ClinicalA Phase 2, Prospective, Multinational, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of AMOR-1 as a Treatment of Hypocalcemia Associated With Hypoparathyroidism by Replacement of Currently Used Calcium Supplements (CS) in Adults.Results expected Q4 2026
- 2026-07-01RegulatoryProduct authorisation ended — Parathyroid HormoneNatpar is indicated as adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.
- 2026-05-18ClinicalAn Expanded Cohort Study on the Safety and Efficacy of mRNA Nucleic Acid Drug XH-02 in Treating Adult HypoparathyroidismResults expected Q2 2030
- 2026-05-11ClinicalA Pilot Study of Calcium Replacement Therapy in Postoperative HypoparathyroidismResults expected Q4 2027
- 2026-03-11ClinicalPhase 2 Study of the PTH-Independent Effects of Encaleret on Mineral Homeostasis in Subjects With Post-Surgical Hypoparathyroidism (PSH)Results posted
- 2026-01-08ClinicalPaTHway CHINA TRIAL: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With HypoparathyroidismCompleted
- 2025-12-31ClinicalTreatment With Indapamide in Patients With Post-Surgical HypoparathyroidismPrimary completion
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Product authorisation ended — Natpar is indicated as adjunctive treatment of adult patients with chronic hypoparathyroi… (2026)
Original application approval — Yorvipath is a parathyroid hormone (PTH) replacement therapy indicated for the treatment… (2023)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes2
- Endocrinology1
- Hypoparathyroidism1
Leading journals1
- European journal of endocrinology1
Leading researchers8
- Bollerslev J1
- Buch O1
- Cardoso LM1
- Dekkers OM1
- Gittoes N1
- Houillier P1
- Makay O1
- Marcocci C1
Affiliations (unnormalised)6
- Aarhus University Hospital1
- and Institute for Research and Innovation in Health of the University of Porto1
- Aristotle University1
- Brigham and Women's Hospital and Harvard Medical School1
- Centre de Recherche des Cordeliers1
- Centre de Référence des Maladies Rares du Calcium et du Phosphate1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Reference
Authoritative identity, definition & identifiers.
A condition caused by a deficiency of PARATHYROID HORMONE (or PTH). It is characterized by HYPOCALCEMIA and hyperphosphatemia. Hypocalcemia leads to TETANY. The acquired form is due to removal or injuries to the PARATHYROID GLANDS. The congenital form is due to mutations of genes, such as TBX1; (see DIGEORGE SYNDROME); CASR encoding CALCIUM-SENSING RECEPTOR; or PTH encoding parathyroid hormone.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.